Lysine demethylases, often abbreviated KDMs, are enzymes that remove methyl chemical groups from lysine residues on histone proteins, the spools around which DNA is wound inside every cell. This seemingly simple act of demethylation has profound consequences for chromatin architecture and gene expression. When KDMs malfunction, the delicate epigenetic balance that governs which genes are switched on or off can be disrupted, contributing to uncontrolled cell proliferation, evasion of programmed cell death, and the development of metastatic behavior. In breast cancer specifically, individual members of this enzyme family have previously been implicated in tumor progression and therapeutic resistance, but a holistic, multi-database portrait of the entire family has been conspicuously lacking.

To construct that portrait, the research team led by investigators at Tabriz University of Medical Sciences harnessed an impressive arsenal of publicly available bioinformatics platforms. They drew upon UALCAN for tumor versus normal expression comparisons, bc-GenExMiner for clinicopathological correlations, the Kaplan-Meier Plotter for survival analyses, cBioPortal for genomic alteration profiling, STRING and Cytoscape for protein interaction network construction, Enrichr for pathway enrichment, MethSurv for CpG methylation survival analysis, GSCALite for drug sensitivity correlations, and TIMER for immune infiltration assessments. All gene names were standardized to HGNC-approved symbols to ensure consistency across the disparate data sources, a methodological safeguard that strengthens the reliability of cross-platform integration.

The analysis revealed that KDM genes do not behave uniformly across breast cancer. Instead, they display sharply divergent expression patterns depending on the molecular subtype of the tumor. Genes including KDM1A, KDM1B, KDM4C, KDM4D, KDM4E, and KDM5A were significantly upregulated in triple-negative and basal-like breast cancers, the most aggressive and hardest-to-treat subtypes, while genes such as KDM2B, KDM3B, KDM4B, KDM6A, and KDM6B were markedly downregulated in the same contexts. Pairwise co-expression analysis within the triple-negative cohort identified two distinct modules: an oncogenic cluster anchored by a strong correlation between KDM1B and KDM5A, and a separate suppressor module linking KDM3B with PHF2. This architecture suggests that groups of demethylases may act cooperatively, either fueling or restraining tumor aggressiveness, rather than functioning as isolated molecular actors.

Survival analysis delivered some of the study’s most clinically resonant findings. Higher expression of KDM1B, KDM4A, KDM4B, KDM5A, KDM5C, KDM6A, and RSBN1 was significantly associated with improved overall survival, with KDM5C showing one of the strongest protective effects. In stark contrast, elevated KDM5B expression predicted shorter overall survival and poorer relapse-free survival, marking it as a candidate adverse prognostic marker. Relapse-free survival analysis extended this picture further, implicating elevated KDM5A, KDM5B, and KDM7A in earlier relapse while confirming the protective associations of more than a dozen other family members. Taken together, these data suggest that a patient’s KDM expression signature could one day inform risk stratification and guide the intensity of adjuvant therapy.

Genomic alteration analysis through cBioPortal, drawing on more than one thousand invasive breast carcinoma samples, identified KDM5B as the most frequently altered KDM gene, with amplification emerging as the dominant mechanism of dysregulation in roughly eighteen percent of tumors. Crucially, alterations in KDM5B, KDM2A, and KDM4C were strongly enriched in metastatic disease, aggressive histologic subtypes including infiltrating ductal and metaplastic carcinomas, and hormone receptor-negative phenotypes. Many of these amplifications and missense mutations clustered within functional domains such as the JmjC catalytic core and DNA-binding regions, implying that the alterations are not passenger events but likely enhance demethylase activity in ways that actively promote tumor progression. Protein interaction network modeling pinpointed KDM6A, KDM6B, KDM1A, KDM1B, and PHF8 as the central regulatory hubs within the broader epigenetic landscape of breast cancer.

Perhaps the most therapeutically provocative dimension of the study involves drug sensitivity. Cross-referencing KDM expression with large pharmacogenomic datasets from the Genomics of Drug Sensitivity in Cancer and Cancer Therapeutics Response Portal revealed that most KDM genes correlate negatively with drug sensitivity, meaning their overexpression may actively foster chemotherapy resistance. KDM2B stood out as the linchpin, showing the strongest and most consistent correlations across both datasets. Elevated KDM2B expression was linked to reduced sensitivity to Methotrexate, Doxorubicin, PX-12, I-BET-762, and Belinostat, clinically relevant agents spanning antifolate, anthracycline, redox-targeting, bromodomain-inhibiting, and HDAC-inhibiting classes. Prior experimental work in glioblastoma and other models has shown that KDM2B inhibition impairs cancer stem-like cell survival by inducing DNA damage and apoptosis, providing a plausible mechanistic rationale for how targeting this enzyme could resensitize tumors to standard chemotherapy.

The study also uncovered a striking methylation dimension. Using MethSurv, the researchers identified dozens of individual CpG sites within KDM genes whose methylation status was significantly associated with patient survival, including thirty-five prognostically relevant CpG sites in KDM2B alone and forty-six in KDM4B. This epigenetic crosstalk between histone demethylase genes and their own DNA methylation patterns underscores the layered complexity of cancer epigenetics and hints at potential biomarker applications beyond simple mRNA measurement. Meanwhile, enrichment analysis confirmed that KDM family genes are centrally involved in histone lysine demethylation, chromatin remodeling, 2-oxoglutarate-dependent dioxygenase activity, and metabolic pathways, connecting these enzymes to the metabolic reprogramming that is increasingly recognized as a hallmark of malignancy.

Immune infiltration analysis through TIMER added yet another layer of significance. KDM5A, KDM6A, and KDM7A expression correlated strongly and positively with CD8-positive T cell infiltration, suggesting these demethylases may help shape anti-tumor immunity. KDM2B showed notable associations with dendritic cells, neutrophils, CD4-positive T cells, and B cells, while KDM6A correlated with macrophage presence. Given the central role of tumor immune microenvironment composition in determining response to immunotherapy, these correlations suggest that KDM expression profiles could eventually help predict which patients are most likely to benefit from immune checkpoint inhibitors. The authors are careful to acknowledge the principal limitation of their work: it is entirely computational, relying on public databases without wet-lab experimental validation. Future studies employing in vitro knockdown assays and in vivo models will be essential to confirm these associations and dissect the underlying molecular mechanisms. Nevertheless, by synthesizing expression, survival, mutation, methylation, drug sensitivity, and immune data into a single unified framework, this investigation delivers the most complete picture to date of how the lysine demethylase family operates in breast cancer, and it does so with a clarity that should accelerate the translation of epigenetic insights into genuinely personalized therapeutic strategies.

The biological significance of lysine demethylation stems from the fact that methylated lysine residues on histone tails can carry distinct methylation states — mono-, di-, or trimethyl — and each state conveys a different transcriptional message. The KDM family reflects this complexity, comprising two mechanistically distinct classes: the flavin adenine dinucleotide-dependent amine oxidases such as KDM1A and KDM1B, and the larger group of JmjC-domain proteins that require iron and 2-oxoglutarate as cofactors. This enzymatic split has practical consequences for drug discovery, since the two classes are inhibited through entirely different chemical strategies, and several small-molecule demethylase inhibitors are already being evaluated in early-phase clinical trials for hematologic and solid malignancies.

The subtype-specific expression patterns observed in this study align with a broader principle in breast cancer biology: epigenetic regulators frequently act in a context-dependent fashion, behaving as oncogenes in one molecular background and tumor suppressors in another. This duality helps explain why broad demethylase inhibition may not be a viable therapeutic strategy, and why a precision approach — one that profiles a patient’s tumor for specific KDM alterations before selecting an epigenetic drug — is likely to be more fruitful.

The strong correlations between KDM expression and immune cell infiltration also connect the family to the emerging field of epigenetic immunomodulation. Chromatin regulators are increasingly understood to control the expression of immune checkpoints, antigen presentation machinery, and cytokine signaling pathways, and combining epigenetic drugs with immune checkpoint blockade has become an active area of clinical investigation. The observed links between KDM5A, KDM6A, and CD8-positive T cell infiltration provide a computational foundation for testing such combinations in breast cancer settings.

It is worth noting that the study’s findings derive entirely from curated patient cohorts within platforms built on The Cancer Genome Atlas and related resources, and the reported effect sizes — such as the hazard ratio of 1.5 for KDM5B — represent statistical associations rather than demonstrated causation. Translating these computationally derived hypotheses into clinical utility will require laboratory validation and, ultimately, prospective testing of KDM-based biomarkers in independent patient populations.

Subject of Research: Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Article Title: Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Article References: Mirzaei, Z., Barati, T., Ebrahimi, A., & Khaniani, M. S. (2026). Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer. Discover Biotechnology, 3(1), Article 9. https://doi.org/10.1007/s44340-026-00055-0

Image Credits: AI Generated

DOI: 10.1007/s44340-026-00055-0

Keywords: Integrated, bioinformatics, profiling, lysine, demethylase, gene, family, breast, cancer, scientific research

Lung adenocarcinoma, a predominant subtype of non-small cell lung cancer, continues to challenge oncologists due to its insidious progression and resistance to conventional therapies. The intrinsic heterogeneity of its microenvironment — comprising cancer cells, immune infiltrates, stromal components, and signaling networks — complicates the understanding of its biology and the development of precision medicine approaches. Against this backdrop, the Ras-association domain family of proteins, known to govern critical cellular signaling pathways that regulate proliferation and apoptosis, emerged as a potential keystone in LUAD pathology.

The investigative team conducted a comprehensive bioinformatics survey across the RASSF family members, pinpointing RASSF2 as a gene of interest with notable downregulation patterns correlating with tumor aggressiveness. To experimentally validate its role, they deployed overexpression strategies in LUAD cell lines, harnessing sophisticated cell proliferation assays including CCK-8 and EdU incorporation tests. These assays revealed a marked suppression of cellular proliferation upon RASSF2 restoration, strongly supporting its candidacy as a tumor suppressor.

Beyond proliferation, the invasive and metastatic potential of LUAD was probed through transwell migration and wound healing assays. The data strikingly demonstrated that RASSF2 overexpression curtails not only cellular migration but also invasion, indicating that RASSF2 influences critical aspects of tumor dissemination. These phenotypic changes underscore the multifaceted impact of RASSF2 in restraining LUAD progression.

Of particular clinical significance is the observation that patients harboring RASSF2 promoter hypermethylation exhibited significantly reduced overall survival compared to those without such methylation. This epigenetic silencing mechanism, which represses gene transcription, was thus linked not only to molecular dysfunction but also to tangible clinical outcomes, highlighting its potential utility as a prognostic biomarker.

To deepen mechanistic insights, transcriptomic profiling via RNA sequencing was performed on LUAD tissue samples stratified by RASSF2 methylation status. The resulting data spotlighted an enrichment of NF-κB signaling pathway components and a concurrent dysregulation of T-cell activation circuits in methylation-positive tumors. Given the central role of NF-κB in inflammation and cancer cell survival, these findings suggest that RASSF2 silencing may unleash pro-tumorigenic inflammatory signaling cascades, while also impairing anti-tumor immune surveillance.

The interplay between epigenetic modifications and immune pathways elucidated in this study paints a complex picture of tumor microenvironment reprogramming. RASSF2 methylation seems to foster an immunosuppressive niche by modulating key signaling cascades that inhibit effective T-cell mediated responses, thereby facilitating immune evasion. This interaction posits RASSF2 as a strategic molecular switch at the crossroads of tumor growth and immune regulation.

Furthermore, the identification of RASSF2 promoter hypermethylation as a determinant of both malignant potential and microenvironmental characteristics introduces new perspectives on LUAD heterogeneity. It advocates for integrating epigenetic profiling into routine diagnostics to better predict disease trajectory and tailor individualized therapeutic regimens focused on reversing methylation marks or targeting downstream inflammatory pathways.

The implications of these findings transcend basic science, as the prospect of targeting epigenetic silencing of RASSF2 holds promise for novel immunotherapeutic strategies. Reactivating this tumor suppressor could restore anti-tumor immunity and potentiate the efficacy of existing immune checkpoint inhibitors, which have revolutionized cancer therapy but still face limitations due to tumor-induced immunosuppression.

Importantly, the study’s methodological rigor — combining robust in vitro assays with high-throughput RNA sequencing and comprehensive clinical correlation — sets a new standard for dissecting the molecular underpinnings of lung cancer. Such integrative approaches are pivotal to decoding the labyrinthine networks that govern tumor behavior and therapeutic resistance.

As the global burden of lung cancer persists, breakthroughs such as these underscore the indispensable role of epigenetics in oncogenesis and pave the way for precision medicine interventions. By illuminating how RASSF2 methylation shapes both the malignant phenotype and the immune milieu, this research invigorates the quest for biomarkers and therapeutics that can transform patient outcomes.

Looking forward, the challenge remains to translate these molecular insights into clinical tools and treatments that are accessible and effective. Ongoing studies will likely explore pharmacological agents capable of demethylating RASSF2 or inhibiting aberrant NF-κB signaling, alongside immunomodulatory therapies designed to reinvigorate T-cell functionality within the tumor microenvironment.

In sum, this seminal research not only validates RASSF2 as a potent tumor suppressor in LUAD but also exposes the intricate epigenetic and immunological mechanisms through which its silencing accelerates disease progression. The convergence of epigenetic regulation and immune evasion illuminated by this work heralds a promising paradigm shift in lung cancer therapeutics, emphasizing the synergy of genetic, epigenetic, and immunologic interventions.

Such discoveries chart a hopeful trajectory toward conquering LUAD’s formidable complexity by targeting the molecular switches at its core, reaffirming the transformative potential of epigenetics in modern oncology. As science advances, the integration of these insights into clinical practice promises to enhance survival rates and quality of life for patients grappling with this devastating disease.

—
Subject of Research: Lung adenocarcinoma (LUAD) and the epigenetic regulation of tumor suppressor gene RASSF2.

Article Title: RASSF2 promoter hypermethylation determines malignant and microenvironmental features in lung cancer.

Article References:
Han, Y., Jiang, W., Chen, Q. et al. RASSF2 promoter hypermethylation determines malignant and microenvironmental features in lung cancer. Genes Immun (2026). https://doi.org/10.1038/s41435-026-00398-y

Image Credits: AI Generated

DOI: 22 April 2026